Rothschild & Co Asset Management US’s Allergan plc AGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-211,510
Closed -$35.4M 361
2019
Q2
$35.4M Sell
211,510
-49,076
-19% -$6.8M 0.38% 106
2019
Q1
$38.2M Buy
260,586
+2,350
+0.9% +$341K 0.41% 84
2018
Q4
$34.5M Sell
258,236
-10,091
-4% -$1.65M 0.42% 72
2018
Q3
$51.1M Buy
268,327
+4,557
+2% +$837K 0.52% 53
2018
Q2
$44M Buy
263,770
+39,650
+18% +$6.37M 0.47% 62
2018
Q1
$37.7M Sell
224,120
-7,447
-3% -$1.25M 0.42% 84
2017
Q4
$37.9M Sell
231,567
-33,892
-13% -$6.08M 0.4% 90
2017
Q3
$54.4M Buy
265,459
+156,839
+144% +$36.5M 0.6% 41
2017
Q2
$26.4M Buy
+108,620
New +$25.5M 0.3% 124
2014
Q3
Sell
-24,629
Closed -$5.49M 363
2014
Q2
$5.49M Buy
24,629
+1,171
+5% +$242K 0.11% 269
2014
Q1
$4.83M Buy
+23,458
New +$4.65M 0.11% 282
2013
Q4
Sell
-10,111
Closed -$1.46M 383
2013
Q3
$1.46M Sell
10,111
-45,371
-82% -$6.04M 0.03% 339
2013
Q2
$7M Buy
+55,482
New +$6.28M 0.16% 209

Other funds holding AGN

Rothschild & Co Asset Management US's AGN Position: Q3 2019 in Review

Rothschild & Co Asset Management US sold out of Allergan plc (AGN) in Q3 2019, closing a stake of 211,510 shares — an estimated $35.4M sold.

Rothschild & Co Asset Management US first reported a position in AGN in Q2 2013 and held it in 13 quarters. The position peaked at $54.4M in Q3 2017. 921 funds tracked by Wall St. Rank hold AGN as of Q3 2019.

  • Rothschild & Co Asset Management US reported no remaining Allergan plc position as of Q3 2019 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 211,510 Allergan plc shares in Q3 2019, an estimated $35.4M.
  • Rothschild & Co Asset Management US first reported a position in Allergan plc in Q2 2013 and held it in 13 quarters.
  • Rothschild & Co Asset Management US's Allergan plc position peaked at $54.4M in Q3 2017.
  • 921 funds tracked by Wall St. Rank held Allergan plc as of Q3 2019.

Based on Rothschild & Co Asset Management US's 13F filing for Q3 2019, filed 8 Nov 2019.